Viginial Microbicide May Provide the Long Awaited Prevention against HIV/AIDS

Must Read

I Didn’t Donate N1billion For Fight Against Covid-19: Peter Obi

Vice Presidential Candidate of the Peoples Democratic Party (PDP) in the last Presidential elections, Peter Obi, says he did...

Japan Begins Clinical Trials For Coronavirus Drug

Japan has begun clinical trials to test the effectiveness of the anti-flu drug Avigan in treating patients with coronavirus,...

Wimbledon Tennis Championship Cancelled Over Coronavirus Pandemic

Wimbledon has been cancelled for because of the coronavirus pandemicThe tournament was due to be played between 29 June...

Coronavirus: UEFA Suspends Champions League, Europa Indefinitely

UEFA has suspended all Champions League and Europa League matches have been suspended "until further notice" because of the...

Coronavirus: Lagos, Abuja, Ogun Markets To Open Between 10:00am and 2:00pm Daily: FG

The Federal Government has made a partial u-turn on the lockdown of markets in Lagos, Ogun and the Federal...
Roti
News is my life; my life is good news!

Ironically, a microbicide gel that is highly effective in blocking infection by HIV in a non-human primate model, could be the key to lasting protection from the virus which causes AIDS, a new study has revealed.

In a paper published in the PLOS Pathogens – an open access journal – Dereuddre-Bosquet and other colleagues from the European Combined Highly Active Anti-Retroviral Microbicides (CHAARM) consortium describe the gel’s key ingredient, which are small peptides engineered to present a decoy to bind up the virus and prevent it from entering and infecting the cells of the body. Because this is a gel it can be topically applied and could represent a powerful preventative agent against sexual transmission of HIV.

For years running now, the scientific community worldwide has been working on the development of a vaccine against HIV. Meanwhile, research is also focused on the reduction of the spread of the virus by the application of a microbicide gel to protect users during intercourse which is usually a time of first exposure to virus. So far, few treatments that block virus entry have shown promising protection.

How it Works
The researchers engineered peptides named “miniCD4s” because they mimic the CD4 receptor used by HIV to gain entry into immune cells of the body. The study shows that the miniCD4s blocks HIV entry into isolated cells in a dish and tissue models that mimic mucous membranes which are points of virus entry.

Then they formulated miniCD4s at 0.3 percent in a microbicide gel that was vaginally applied to six female cynomolgus macaques monkeys for one hour before the animals were given a high dose of the virus also in the vagina.

This dose would ordinarily make the animals highly infected but instead, five of the six were completely protected from HIV infection. No trace of virus was found in any body tissue. They were also unable to detect any antibodies to the virus in the plasma of the animals, indicating that the virus was completely repelled and there was full protection.

This study provides a proof of principle that for a promising strategy for the prevention and protection against HIV transmission during sexual intercourse. Importantly, the protection was demonstrated in a non human primate model which represents an essential step prior needed to progress to a prospective clinical trial.

Culled from the Vanguard

- Advertisement -

3 COMMENTS

LEAVE A REPLY

Please enter your comment!
Please enter your name here

More Articles Like This

- Advertisement -